# Evogene Ltd. (EVGN)

Source page: https://stoqly.net/companies/evgn

- **Ticker:** EVGN (Nasdaq)
- **Sector:** Materials / Agricultural Chemicals
- **SEC CIK:** 0001574565
- **Latest annual report:** 20-F filed 2026-03-26 (https://www.sec.gov/Archives/edgar/data/1574565/000117891326001767/zk2634882.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $0.37 on 2026-10-30
- **Market cap:** $2.9M
- **P/E (trailing):** 0.3x
- **EPS, trailing 12 months:** $1.08
- **Revenue (FY2025):** $3.9M
- **Revenue growth:** −30.9%
- **Revenue growth, 5-year CAGR:** +29.9%
- **Gross margin:** −6.3%
- **Operating margin:** −364.2%
- **Net margin:** −220.2%
- **Free cash flow:** −$13.6M
- **Free cash flow margin:** −353.9%
- **Change in share count:** +38.2%
- **Piotroski F-score:** 2/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/evgn/figures.csv

| US$ millions | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | 7 | 3 | 2 | 1 | 1 | 1 | 2 | 3 | 6 | 4 |
| Operating income | -21 | -22 | -20 | -21 | -25 | -31 | -27 | -22 | -19 | -14 |
| Net income | -20 | -21 | -21 | -18 | -23 | -28 | -27 | -24 | -16 | -8 |
| Diluted EPS (US$) | -0.77 | -0.81 | -0.81 | -0.70 | -0.83 | -0.69 | -6.44 | -5.20 | -2.90 | 1.08 |
| Operating cash flow | -12 | -16 | -15 | -18 | -20 | -25 | -24 | -22 | -20 | -14 |
| Free cash flow | -13 | -17 | -16 | -19 | -20 | -26 | -25 | -22 | -20 | -14 |
| Cash | 3 | 3 | 6 | 35 | 46 | 32 | 29 | 21 | 15 | 13 |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.